Dopamine Neuron VGLUT2 Expression in Parkinson's Disease
Dopamine Neuron VGLUT2 Expression in Parkinson's Disease
批准号:
10473510
负责人:
Silas Buck
金额:
$4.68万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
已结题
起止时间:
2021-04-01 至 2024-03-31
关键词:
AffectAgeAgingAnimal ModelAutopsyBehaviorBrainCellsDataDisease modelDopamineDrosophila genusEvolutionExhibitsExperimental ModelsFemaleFutureGlutamatesGoalsHumanImpairmentLinkLocomotionLongevityMammalsMeasuresMediatingMidbrain structureModelingNerve DegenerationNeurodegenerative DisordersNeuronsNeurotoxinsOxidopamineParaquatParkinson DiseasePatientsPesticidesPlayPrimatesPropertyRNA InterferenceResearchResearch PersonnelResistanceRisk FactorsRodentRoleSex DifferencesSubstantia nigra structureSymptomsSystemTestingToxinTrainingTranslatingTranslationsTyrosine 3-MonooxygenaseUp-RegulationVentral Tegmental Areabehavioral responsebrain researchbrain tissueconditional knockoutdopaminergic neuroneffective therapyexperimental studyflyhuman femalein vivoknock-downlocomotor deficitmRNA Expressionmalemotor deficitmotor impairmentneuron lossneuroprotectionneurotoxicnew therapeutic targetnext generationnonhuman primatenovelpars compactapreventprogrammed cell death protein 1resilienceresponsesexsexual dimorphismstressortooltreatment strategyvesicular glutamate transporter 2
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
In Parkinson’s Disease (PD), dopamine (DA) neurons degenerate in the substantia nigra pars compacta (SNc).
In contrast, the DA neurons of the ventral tegmental area (VTA) are relatively protected from PD-induced
degeneration, but the cause of this neuroprotection is unknown. One possible answer may derive from the unique
properties of VTA DA neurons: a subset of these cells co-release glutamate and express the vesicular glutamate
transporter 2 (VGLUT2). DA neurons that express VGLUT2 are more likely to survive neurotoxic insult in animal
models of PD, and DA neuron VGLUT2 upregulation is observed in neurons resilient to DA neurotoxins.
Significantly, VGLUT2 expression is upregulated in DA neurons across Drosophila, rodents, non-human and
human primates in response to cell stressors, suggesting that this an evolutionarily-conserved mechanism that
confers protection against DA neuron degeneration. Moreover, in Drosophila, I discovered females express more
Drosophila VGLUT (dVGLUT) compared to males. I also found males flies are markedly more vulnerable to DA
neuron degeneration and exhibit more motor deficits compared to females in DA neurotoxin models of PD [e.g.,
paraquat and 6-hydroxydopamine (6OHDA)] analogous to the sex-specific sequelae of human PD. These
findings indicate that VGLUT2 expression is likely part of a regulatory mechanism that may protect these cells
and that likely impacts sex differences in PD. These data also show the genetically tractable fly model can be
utilized as a powerful experimental system to investigate mechanisms of DA neuron resilience and vulnerability
in PD. Given VGLUT’s roles in DA neuron resilience, the central goals of this proposal are to identify: 1)
how DA neuron VGLUT expression impacts DA neuron vulnerability, 2) whether the sex differences in
DA neuron resilience depend on differences in DA neuron VGLUT expression, and 3) how DA neuron
VGLUT2 expression changes in human PD. I will test the hypothesis that DA neuron VGLUT expression
confers increased protection in DA neurons, especially in females since they express more VGLUT
compared to males. The long-term goals of this proposal are to i) determine the role of VGLUT in mediating
vulnerability and sex differences in response to 6OHDA and paraquat in the fly model (Aim 1), and ii), measure
DA neuron VGLUT2 expression in human PD (Aim 2). To test these goals, I will use RNA-interference to knock
down dVGLUT expression in Drosophila DA neurons, and measure DA neuron vulnerability in male versus
female flies in 6OHDA and paraquat PD models. In parallel, I will measure DA neuron VGLUT2 expression in
human PD using postmortem human midbrain of both male and female PD patients and matched controls. These
experiments will establish DA neuron VGLUT expression as a novel mechanism of neuroprotection in PD,
leading to new, more effective therapies to prevent or mitigate the DA neurodegenerative effects of PD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dopamine Neuron VGLUT2 Expression in Parkinson's Disease
-
批准号:10230463
-
项目类别:
-
资助金额:$4.6万
-
财政年份:2021
-
负责人:Silas Buck
-
依托单位:
Dopamine Neuron VGLUT2 Expression in Parkinson's Disease
-
批准号:10608204
-
项目类别:
-
资助金额:$3.1万
-
财政年份:2021
-
负责人:Silas Buck
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: